| Schmerzm. | Schlafm. | Beruhigungsm. | Antidepr. | Anregungsm. | Schlankm. | Abführm. | Anabolika | Hustensedat. | |
| 1996* | 21.6 | 4.9 | 3.0 | 1.6 | 0.0 | 0.3 | 4.3 | 0.0 | 4.3 |
| 1997* | 21.3 | 4.8 | 3.0 | 1.8 | 0.0 | 0.3 | 4.2 | 0.0 | 4.7 |
| 1998* | 21.1 | 4.7 | 3.0 | 2.1 | 0.0 | 0.3 | 4.0 | 0.0 | 4.3 |
| 1999* | 22.0 | 4.7 | 3.1 | 2.4 | 0.1 | 0.5 | 4.0 | 0.0 | 4.5 |
| 2000* | 21.3 | 4.7 | 3.1 | 2.5 | 0.1 | 0.5 | 4.2 | 0.0 | 4.0 |
| 2001* | 21.9 | 4.8 | 3.1 | 2.5 | 0.1 | 0.4 | 4.4 | 0.0 | 3.8 |
| 2002* | 21.6 | 4.6 | 3.1 | 2.6 | 0.1 | 0.3 | 4.4 | 0.0 | 3.7 |
| 2003* | 22.3 | 4.6 | 3.1 | 2.7 | 0.1 | 0.3 | 4.3 | 0.0 | 3.8 |
| 2004 | 21.0 | 4.6 | 3.0 | 2.7 | 0.1 | 0.3 | 4.2 | 0.0 | 3.4 |
| 2005 | 21.6 | 4.5 | 3.0 | 2.7 | 0.2 | 0.3 | 4.1 | 0.0 | 3.5 |
| 2006 | 22.1 | 4.5 | 3.0 | 2.8 | 0.2 | 0.2 | 4.1 | 0.0 | 3.2 |
| 2007 | 23.1 | 4.5 | 3.0 | 2.9 | 0.2 | 0.2 | 4.3 | 0.0 | 3.4 |
| 2008 | 23.3 | 4.5 | 3.0 | 3.1 | 0.3 | 0.2 | 4.4 | 0.0 | 3.3 |
| 2009 | 23.4 | 4.5 | 2.9 | 3.1 | 0.3 | 0.2 | 4.3 | 0.0 | 3.8 |
| 2010 | 22.7 | 4.6 | 2.9 | 3.2 | 0.3 | 0.2 | 4.4 | 0.0 | 3.4 |
| 2011 | 23.0 | 4.5 | 2.9 | 3.3 | 0.3 | 0.1 | 4.4 | 0.0 | 3.4 |
| 2012 | 22.3 | 4.5 | 2.8 | 3.3 | 0.3 | 0.1 | 4.4 | 0.0 | 3.1 |
| 2013 | 22.6 | 4.5 | 2.7 | 3.4 | 0.3 | 0.1 | 4.3 | 0.0 | 3.5 |
| 2014 | 22.0 | 4.5 | 2.7 | 3.5 | 0.3 | 0.1 | 4.3 | 0.0 | 3.0 |
| 2015 | 21.9 | 4.5 | 2.6 | 3.5 | 0.3 | 0.1 | 4.3 | 0.0 | 3.3 |
| 2016 | 21.9 | 4.5 | 2.5 | 3.6 | 0.4 | 0.1 | 4.3 | 0.0 | 3.1 |
| 2017 | 20.9 | 4.5 | 2.5 | 3.6 | 0.4 | 0.0 | 4.2 | 0.0 | 2.8 |
| 2018 | 20.9 | 4.5 | 2.4 | 3.7 | 0.4 | 0.1 | 4.3 | 0.0 | 2.9 |
| in Mio. CHF auf Basis der Herstellerab- gabepreise** | 102.1 | 40.8 | 14.3 | 143.6 | 26.0 | 4.7 | 34.1 | 0.0 | 16.1 |
| Anmerkungen: | * Ein 2004 neu eingeführtes Berechnungsverfahren erschwert Vergleiche zwischen den beiden Perioden. ** Daten 2018 |
| Quelle: | Interpharma: persönliche Mitteilung |